Theralase® Technologies Inc. announced that Urology Associates P.C. has received site Institutional Review Board approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer Clinical Study to enroll and treat patients with Bacillus Calmette Guerin-Unresponsive Carcinoma In-Situ or are intolerant to BCG Therapy. Theralase has central IRB approval to launch a number of US clinical sites, subject to local site IRB approval. UA is the second site to receive both central and local site IRB approval. There are 4 additional US clinical study sites that have received central IRB approval and are expected to receive local IRB approval in 1Q2021. Founded in the 1940s, Urology Associates, P.C. serves Middle Tennessee with over 20 board-certified urologists and 12 Advanced Practice Providers, providing male and female urological care in over 10 locations. They were the first practice to open a center solely dedicated to female urology in Nashville. Urology Associates are committed to the innovation and the integration of advanced technology and advanced therapeutics in their treatment offerings. The practice provides unique treatment options and specialized care in their Urology Surgery Center, Women's Institute for Sexual Health (WISH) and Advanced Therapeutics Center. Urology Associates, P.C. was founded on the principles of compassionate, high-quality urological care, and continues to serve that mission. To date 14 patients have been treated in Study II. With the addition of UA, the Company now has 5 clinical study sites open in Canada and 2 in the US for patient enrollment and treatment.